Edit Entry

Michael B. Sporn, M.D.

Title(s):
Professor of Pharmacology & Toxicology
Professor of Medicine

Department(s):
Pharmacology & Toxicology
Medicine

Education:
Harvard University, AB 1952
U. Rochester School of Medicine & Dentistry, MD 1959

Programs:
Norris Cotton Cancer Center
Pharmacology and Toxicology Graduate Program
Program in Experimental and Molecular Medicine

Websites:
http://geiselmed.dartmouth.edu/pharmtox
http://geiselmed.dartmouth.edu/sporn

Contact Information:

7650 Remsen
Dept. of Pharmacology and Toxicology
Geisel School of Medicine
Hanover NH 03755

Office: Remsen 524A
Phone: 603-650-6557
Fax: 603-650-1129
Email: michael.sporn@dartmouth.edu

Assistant: Caitlin Kivler
Asst. Phone: 603-650-6559
Asst. Email: Caitlin.Kivler@Dartmouth.edu


Professional Interests:

Chemoprevention of cancer, especially by retinoids, rexinoids, and other ligands of the steroid receptor superfamily; peptide growth factors, especially transforming growth factor-beta (TGF-beta) and its mechanism of action; development of new natural products for prevention of cancer. Synthetic triterpenoids and rexinoids (RXR ligand) as anti-inflammatory, anti-oxidative, and anti-carcinogenic agents.

Dr. Sporn completed his undergraduate studies at Harvard College, majoring in biology, in 1952. He received his M.D. at the University of Rochester in 1959. Dr. Sporn then began his research career at the National Institutes of Health, where, in 1970, he was made the Head of the Lung Cancer Unit. In 1978 he became Chief of the Laboratory of Chemoprevention, where he remained until 1995, when he came to Dartmouth Medical School as the Oscar M. Cohn '34 Professor of Pharmacology and Medicine.

Triterpenoids of an ursane or oleanane structure are widely distributed in nature, occurring in hundreds of plants all over the world. Many such structures have interesting biological, pharmacological, or medicinal activities, similar to those of retinoids and steroids, including inhibition of carcinogenesis and induction of differentiation in leukemia or teratocarcinoma cells. Ursanes and oleananes belong to a larger family of related terpenoids, many of which are ligands for the steroid receptor superfamily, such as retinoids and classical steroids.

In collaboration with Professor Gordon Gribble in the Department of Chemistry, we are studying ursanes and oleananes that are more polar than the common parent substances, ursolic acid and oleanolic acid. The goal of these studies is to understand the mechanism of action of triterpenoids, and also to develop new agents for prevention of cancer and other degenerative diseases. One of the new synthetic triterpenoids that has been made for the first time in the Department of Chemistry is now in clinical trials for the treatment of advanced diabetic kidney disease. Karen Liby, Associate Professor of Pharmacology, is a key collaborator in the Sporn Lab


Selected Publications:

 

So JY, Lin JJ, Wahler J, Liby KT, Sporn MB, Suh N
A Synthetic Triterpenoid CDDO-Im Inhibits Tumorsphere Formation by Regulating Stem Cell Signaling Pathways in Triple-Negative Breast Cancer.
PLoS One 2014; 9(9):e107616
PMID: 25229616

Fu L, Lin QX, Liby KT, Sporn MB, Gribble GW
An efficient synthesis of methyl 2-cyano-3,12-dioxoursol-1,9-dien-28-oate (CDDU-methyl ester): analogues, biological activities, and comparison with oleanolic acid derivatives.
Org Biomol Chem 2014 Jul 28; 12(28):5192-200
PMID: 24915424

To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
Cancer Prev Res (Phila) 2014 Jul; 7(7):698-707
PMID: 24817481

Johnson NM, Egner PA, Baxter VK, Sporn MB, Wible RS, Sutter TR, Groopman JD, Kensler TW, Roebuck BD
Complete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold.
Cancer Prev Res (Phila) 2014 Jul; 7(7):658-65
PMID: 24662598

Onyango EO, Fu L, Cao M, Liby KT, Sporn MB, Gribble GW
Synthesis and biological evaluation of amino acid methyl ester conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid against the production of nitric oxide (NO).
Bioorg Med Chem Lett 2014 Jan 15; 24(2):532-4
PMID: 24388806

Liu M, Reddy NM, Higbee EM, Potteti HR, Noel S, Racusen L, Kensler TW, Sporn MB, Reddy SP, Rabb H
The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice.
Kidney Int 2014 Jan; 85(1):134-41
PMID: 24088953

Sporn MB, Liby KT
Is lycopene an effective agent for preventing prostate cancer?
Cancer Prev Res (Phila) 2013 May; 6(5):384-6
PMID: 23483003

Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB, Schwartz GN, Wells WA, Sempere LF, Yu PB, DiRenzo J
ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells.
Cancer Res 2013 Jan 15; 73(2):1020-30
PMID: 23243027

Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
Carcinogenesis 2013 Jan; 34(1):199-210
PMID: 23042302

Liby KT, Sporn MB
Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.
Pharmacol Rev 2012 Oct; 64(4):972-1003
PMID: 22966038